PT  - JOURNAL ARTICLE
AU  - Patel, Mehul D.
AU  - Rosenstrom, Erik
AU  - Ivy, Julie S.
AU  - Mayorga, Maria E.
AU  - Keskinocak, Pinar
AU  - Boyce, Ross M.
AU  - Lich, Kristen Hassmiller
AU  - Smith, Raymond L.
AU  - Johnson, Karl T.
AU  - Swann, Julie L.
TI  - The Joint Impact of COVID-19 Vaccination and Non-Pharmaceutical Interventions on Infections, Hospitalizations, and Mortality: An Agent-Based Simulation
AID  - 10.1101/2020.12.30.20248888
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.30.20248888
4099  - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20248888.short
4100  - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20248888.full
AB  - Background Vaccination against SAR-CoV-2 has the potential to significantly reduce transmission and COVID-19 morbidity and mortality. This modeling study simulated the comparative and joint impact of COVID-19 vaccine efficacy and coverage with and without non-pharmaceutical interventions (NPIs) on total infections, hospitalizations, and deaths.Methods An agent-based simulation model was employed to estimate incident SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths over 1.5 years for the State of North Carolina, a population of roughly 10.5 million. Vaccine efficacy of 50% and 90% and vaccine coverage of 25%, 50%, and 75% (at the end of a 6-month distribution period) were evaluated. Six vaccination scenarios were simulated with NPIs (i.e., reduced mobility, school closings, face mask usage) maintained and removed during the period of vaccine distribution.Results In the worst-case vaccination scenario (50% efficacy and 25% coverage), approximately 2.2 million new SARS-CoV-2 infections occurred with NPIs removed and approximately 900,000 infections with NPIs maintained. In contrast, in the best-case scenario (90% efficacy and 75% coverage), there were 458,087 new infections with NPIs maintained and 535,019 with NPIs maintained. When NPIs were removed, 50% efficacy and 75% coverage reduced infection risk by a greater magnitude than 90% efficacy and 25% coverage (absolute risk reduction 13% and 8%, respectively).Conclusion Simulation results suggest that, as NPIs are removed, higher vaccination coverage with less efficacious vaccines can contribute to a larger reduction in risk of SAR-CoV-2 infection than compared to more efficacious vaccines at lower coverage. Furthermore, premature lifting of NPIs while vaccines are distributed may result in substantial increases in infections, hospitalizations, and deaths. Overall, our findings highlight the need for well-resourced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs to end the current pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through Grant Award Number UL1TR002489. The work was also supported by a grant from the Council of State and Territorial Epidemiologists and the Centers for Disease Control and Prevention. Dr. Patel is supported by NCATS, NIH, through Grant KL2TR002490. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, CSTE, CDC, or the universities employing the researchers.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was determined to be exempt from IRB review by the UNC Office of Human Research Ethics.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript utilizes publicly available data sources and model parameters from the literature. All sources are cited in the manuscript.